These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 30192805)

  • 21. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
    Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P
    Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Post-kala-azar dermal leishmaniasis in a patient treated with injectable paromomycin for visceral leishmaniasis in India.
    Pandey K; Das VN; Singh D; Das S; Lal CS; Verma N; Bimal S; Topno RK; Siddiqui NA; Verma RB; Sinha PK; Das P
    J Clin Microbiol; 2012 Apr; 50(4):1478-9. PubMed ID: 22278840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The usefulness of trained field workers in diagnosis of post-kala-azar dermal leishmaniasis (PKDL) and clinico-epidemiological profile in highly endemic areas of Bihar.
    Das VNR; Siddiqui NA; Pandey K; Lal CS; Sinha SK; Bimal S; Topno RK; Singh SK; Kumar S; Das P
    Trans R Soc Trop Med Hyg; 2019 Jun; 113(6):332-340. PubMed ID: 30920625
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and immunological aspects of post-kala-azar dermal leishmaniasis in Bangladesh.
    Islam S; Kenah E; Bhuiyan MA; Rahman KM; Goodhew B; Ghalib CM; Zahid MM; Ozaki M; Rahman MW; Haque R; Luby SP; Maguire JH; Martin D; Bern C
    Am J Trop Med Hyg; 2013 Aug; 89(2):345-53. PubMed ID: 23817330
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Visceral leishmaniasis, or kala azar (KA): high incidence of refractoriness to antimony is contributed by anthroponotic transmission via post-KA dermal leishmaniasis.
    Singh R; Kumar D; Ramesh V; Negi NS; Singh S; Salotra P
    J Infect Dis; 2006 Aug; 194(3):302-6. PubMed ID: 16826477
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinico-epidemiological analysis of Post kala-azar dermal leishmaniasis (PKDL) cases in India over last two decades: a hospital based retrospective study.
    Ramesh V; Kaushal H; Mishra AK; Singh R; Salotra P
    BMC Public Health; 2015 Oct; 15():1092. PubMed ID: 26503551
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PKDL--A Silent Parasite Pool for Transmission of Leishmaniasis in Kala-azar Endemic Areas of Malda District, West Bengal, India.
    Ganguly S; Saha P; Chatterjee M; Roy S; Ghosh TK; Guha SK; Kundu PK; Bera DK; Basu N; Maji AK
    PLoS Negl Trop Dis; 2015; 9(10):e0004138. PubMed ID: 26485704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL).
    Musa AM; Khalil EA; Mahgoub FA; Hamad S; Elkadaru AM; El Hassan AM
    Ann Trop Med Parasitol; 2005 Sep; 99(6):563-9. PubMed ID: 16156969
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Post-kala-azar dermal leishmaniasis and leprosy: case report and literature review.
    Trindade MA; Silva LL; Braz LM; Amato VS; Naafs B; Sotto MN
    BMC Infect Dis; 2015 Nov; 15():543. PubMed ID: 26592919
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liposomal amphotericin B is more effective in polymorphic lesions of post kala-azar dermal leishmaniasis.
    Moulik S; Sengupta R; Ghosh MK; Das NK; Saha B; Chatterjee M
    Indian J Dermatol Venereol Leprol; 2022; 88(2):201-206. PubMed ID: 33969651
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Visceral and post-Kala-Azar dermal leishmaniasis isolates show significant difference in their in vitro drug susceptibility pattern.
    Mishra J; Madhubala R; Singh S
    Parasitol Res; 2013 Mar; 112(3):1001-9. PubMed ID: 23242321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Visceral Leishmaniasis-HIV Coinfection as a Predictor of Increased
    Cloots K; Marino P; Burza S; Gill N; Boelaert M; Hasker E
    Front Cell Infect Microbiol; 2021; 11():604117. PubMed ID: 33777831
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The safety and efficacy of miltefosine in the long-term treatment of post-kala-azar dermal leishmaniasis in South Asia - A review and meta-analysis.
    Pijpers J; den Boer ML; Essink DR; Ritmeijer K
    PLoS Negl Trop Dis; 2019 Feb; 13(2):e0007173. PubMed ID: 30742620
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Study on the safety and efficacy of miltefosine for the treatment of children and adolescents with post-kala-azar dermal leishmaniasis in Bangladesh, and an association of serum vitamin E and exposure to arsenic with post-kala-azar dermal leishmaniasis: an open clinical trial and case-control study protocol.
    Mondal D; Hasnain MG; Hossain MS; Ghosh D; Ghosh P; Hossain H; Baker J; Nath R; Haque R; Matlashewski G; Hamano S
    BMJ Open; 2016 May; 6(5):e010050. PubMed ID: 27188804
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Kala-azar and post-kala-azar dermal leishmaniasis, Assam, India.
    Khan AM; Dutta P; Khan SA; Baruah SK; Raja D; Khound K; Mahanta J
    Emerg Infect Dis; 2014 Mar; 20(3):487-9. PubMed ID: 24565057
    [No Abstract]   [Full Text] [Related]  

  • 36. Enhanced case detection and improved diagnosis of PKDL in a Kala-azar-endemic area of Bangladesh.
    Mondal D; Nasrin KN; Huda MM; Kabir M; Hossain MS; Kroeger A; Thomas T; Haque R
    PLoS Negl Trop Dis; 2010 Oct; 4(10):. PubMed ID: 20957193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of miltefosine in treatment of post-kala-azar dermal leishmaniasis.
    Sundar S; Singh A; Chakravarty J; Rai M
    ScientificWorldJournal; 2015; 2015():414378. PubMed ID: 25685839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Visceral leishmaniasis follow-up and treatment outcomes in Tiaty East and West sub-counties, Kenya: Cure, relapse, and Post Kala-azar Dermal Leishmaniasis.
    Kennedy GC; O'Brien K; Nyakundi H; Kitondo M; Biwott W; Wamai RG
    PLoS One; 2024; 19(6):e0306067. PubMed ID: 38917127
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic heterogeneity among visceral and post-Kala-Azar dermal leishmaniasis strains from eastern India.
    Dey A; Singh S
    Infect Genet Evol; 2007 Mar; 7(2):219-22. PubMed ID: 17027344
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Post-kala-azar dermal leishmaniasis (PKDL): the first case report from Nepal.
    Karki P; Koirala S; Parija SC; Sethi M; Das ML
    Southeast Asian J Trop Med Public Health; 2003 Mar; 34(1):22-3. PubMed ID: 12971510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.